Title: Synergic
effects of anticancer peptide CIGB-552 and Cisplatin in lung cancer
models
Authors: Yolanda Gomez
Rodriguez1,
Brizaida
Oliva Arguelles2*, Mario
Riera-Romo3*,
Jorge
Fernandez-De-Cossio4,
Freya Milagro Freyre
Almeida5, Yaima
Chacon Quintero6, Amalia Vazquez
Arteaga5, Tania Cardenas Borrego6,
Rocio Garateix Suarez6,
Enma Brown
Richards7, Dagmara Pichardo Diaz7,
Lizet Aldana Velazco7,
Hilda Elisa
Garay8, Julio Fernandez Masso2,
Maribel Guerra Vallespi2.
1 Pavillon de Recherche Appliquée sur le Cancer
(PRAC), Université de Sherbrooke, Québec, Canada.
2 Pharmaceutical Department, Laboratory of Cancer
Biology, Center for Genetic Engineering and Biotechnology (CIGB),
Havana, Cuba.
3 Radiology Department, Leiden University Medical
Center (LUMC), Leiden, The Netherlands.
4 Department of Bioinformatics,
Center
for Genetic Engineering and Biotechnology (CIGB), Havana, Cuba.
5 Analytical
laboratory, Chemical-Physical Department, Center for Genetic Engineering
and Biotechnology (CIGB), Havana, Cuba.
6 Vaccine Department, Center for Genetic Engineering
and Biotechnology (CIGB), Havana, Cuba.
7 Animal Facility Department,
Center for Genetic Engineering and
Biotechnology (CIGB), Havana, Cuba.
8 Peptide Synthesis Division, Center for Genetic
Engineering and Biotechnology (CIGB), Havana, Cuba.
*Correspondence to:Brizaida Oliva Arguelles,
Laboratory of Cancer Biology, Center for Genetic Engineering and
Biotechnology (CIGB), Cubanacan, P.O. Box 6162, 10600 Havana, Cuba.Email:brizaida.oliva@gmail.com,
brizaida.oliva@cigb.edu.cu
*Mario Riera-Romo, Leiden
University Medical Center (LUMC), P.O. Box 9600, 2300 RC Leiden, The
Netherlands, Email:rieraromo@gmail.com,
M.Riera_Romo@lumc.nl